glp-1 receptor agonist and dpp-4 inhibitor combination not recommended do combine inhibitors with agonists guidance What classes of diabetes GLP-1 receptor agonists vs. DPP-4
Description
Diabetes 64 , 715717 (2015)

Many participants in the trials achieved excellent results at 8 mg without needing to escalate to the 12 mg maximum, which suggests that the highest dose is not necessary or appropriate for everyone
adherence and sustainability determine long-term success

Klebanoff: We are studying GLP-1 prior authorization policies across U.S

Initially developed for Type 2 Diabetes (T2D), GLP-1 drugs are now widely used in obesity/weight loss management, with emerging applications in cardiovascular and neurodegenerative diseases

Between these, Novo Nordisk may have the more recognizable brands in the GLP-1 space, as it is the maker of both Ozempic and Wegovy
